Saturday, June 28, 2025
29.4 C
London
HomeFinTechGeneos Therapeutics: Raises $12M in Series A1 Financing

Geneos Therapeutics: Raises $12M in Series A1 Financing

Date:

UK Tribunal Rules Visa and Mastercard Interchange Fees Breach Competition Law

Landmark decision finds payment giants’ multilateral interchange fees unlawful,...

UK Tribunal Rules Visa and Mastercard Fees Violate Competition Law

Landmark Decision Could Reshape Payment Processing LandscapeHighlights: The UK...

Belgium Prosecutors Investigate Worldline Local Unit for Potential Misconduct

An In-Depth Look into the Probe and Its Implications...
  • Geneos Therapeutics, Pa.-based clinical stage company, closed its Series A1 round, raising $12m in financing
  • The round led by Korea Investment Partners– Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc
  • In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners USA Inc. joined Geneos’ Board of Directors
  • Geneos Therapeutics  also develops personalized therapies for cancer using its GT-EPIC™ platform to target unique neoantigens from individual patient tumors
  • The company’s GT-EPIC Neoantigen-Targeting Platform is based on a clinically-validated DNA medicines technology exclusively licensed from Inovio Pharmaceuticals, Inc

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories